Shares of MaxCyte, Inc. (LON:MXCT - Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 322.33 ($4.16) and traded as low as GBX 242 ($3.13). MaxCyte shares last traded at GBX 243.10 ($3.14), with a volume of 9,254 shares traded.
MaxCyte Trading Down 6.2 %
The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38. The stock has a market cap of £316.85 million, a price-to-earnings ratio of -8.80 and a beta of 1.13. The business's 50 day moving average is GBX 320.49 and its 200 day moving average is GBX 306.83.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Read More
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
